Articles By Anuja Singh
Will GE HealthCare’s Acquisition of icometrix Redefine AI-Powered Neurology Imaging?
Chicago – GE HealthCare (Nasdaq: GEHC) announced it has entered into a definitive agreement to acquire icometrix, a…
ByCan BD’s Expanded Recall of Alaris™ Pump Infusion Sets Trigger a Turning Point in…
Key Insights BD’s updated recall follows internal testing that revealed infusion performance deviations, including flow rate accuracy issues,…
Can Johnson & Johnson’s Pact with Pacira BioSciences Redefine Early Intervention for Knee Osteoarthritis?
Key Insights Expanding Non-Surgical Pathways Through this agreement, Johnson & Johnson MedTech integrates ZILRETTA® into its Early Intervention…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences…
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
Will GE HealthCare’s Acquisition of icometrix Redefine AI-Powered Neurology Imaging?
Chicago – GE HealthCare (Nasdaq: GEHC) announced it has entered into a definitive agreement to acquire icometrix, a…
Can BD’s Expanded Recall of Alaris™ Pump Infusion Sets Trigger a Turning Point in…
Key Insights BD’s updated recall follows internal testing that revealed infusion performance deviations, including flow rate accuracy issues,…
Can Johnson & Johnson’s Pact with Pacira BioSciences Redefine Early Intervention for Knee Osteoarthritis?
Key Insights Expanding Non-Surgical Pathways Through this agreement, Johnson & Johnson MedTech integrates ZILRETTA® into its Early Intervention…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences…
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…